Tectonic Therapeutic, Inc.

Equities

AVRO

US8789721086

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 15:35:52 2024-06-27 EDT			5-day change	1st Jan Change
16.4 ^USD	+2.92%		-6.51%	-2.39%

06-20	Avrobio Closes Merger With Tectonic Therapeutic	MT
06-20	Tectonic Therapeutic, Inc. announced that it has received $96.599856 million in funding from Tas Partners, LLC	CI

AVROBIO, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 09, 2024 at 04:31 pm

AVROBIO, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 6.81 million compared to USD 24.96 million a year ago. Basic loss per share from continuing operations was USD 1.8 compared to USD 6.84 a year ago.

Latest news about Tectonic Therapeutic, Inc.

Avrobio Closes Merger With Tectonic Therapeutic	06-20	MT
Tectonic Therapeutic, Inc. announced that it has received $96.599856 million in funding from Tas Partners, LLC	06-19	CI
AVROBIO, Inc.(NasdaqGS:AVRO) dropped from NASDAQ Composite Index	06-19	CI
Tectonic Therapeutic, Inc. completed the acquisition of AVROBIO, Inc. from a group of shareholders in a reverse merger transaction.	06-19	CI
Avrobio Insider Bought Shares Worth $971,493, According to a Recent SEC Filing	05-15	MT
AVROBIO, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
North American Morning Briefing : Investors -2-	03-21	DJ
AVROBIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-14	CI
Transcript : AVROBIO, Inc., Tectonic Therapeutic, Inc. - M&A Call	01-30
Tectonic Therapeutic, Inc. announced that it expects to receive $96.599856 million in funding from Tas Partners, LLC	01-29	CI
AVROBIO, Inc. entered into an agreement to acquire Tectonic Therapeutic, Inc.	01-29	CI
North American Morning Briefing : S&P 500 Eyes -2-	12-19	DJ
Mizuho Securities Cuts Avrobio Price Target to $2 From $5, Buy Rating Kept	12-18	MT
North American Morning Briefing : Caution Dominates Ahead of CPI Print	11-14	DJ
AVROBIO, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
North American Morning Briefing : China Angst -2-	23-08-15	DJ
AVROBIO, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Wells Fargo Adjusts Price Target on AVROBIO to $2 From $2.50, Maintains Overweight Rating	23-07-13	MT
North American Morning Briefing : Optimism Set to -2-	23-07-13	DJ
Sector Update: Health Care Stocks Slipping Late Wednesday	23-07-12	MT
Sector Update: Health Care Stocks Softer in Afternoon Trading	23-07-12	MT
Wedbush Downgrades AVROBIO to Neutral From Outperform on Halted Development of Gene Therapy Programs, Exploring Alternatives; PT is $2	23-07-12	MT
AVROBIO Says Exploring Strategic Alternatives to Boost Shareholder Value; Shares Jump	23-07-12	MT
Avrobio to Conduct Exploration of Strategic Alternatives	23-07-12	CI
AVROBIO, Inc.(NasdaqGS:AVRO) dropped from Russell Microcap Index	23-06-23	CI

Chart Tectonic Therapeutic, Inc.

Duration

Period

More charts

Company Profile

Tectonic Therapeutic, Inc. is a biotechnology company. The Company is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Leveraging its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), the Company is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. The Companyâs lead program, TX000045 (TX45), is an Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. TX45 is being evaluated in Phase Ia/Ib clinical trials as a potential treatment for Group 2 Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (HFpEF). Its second program addresses Hereditary Hemorrhagic Telangiectasia (HHT).

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

15.93 USD

Average target price

76 USD

Spread / Average Target

+377.09%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
TECTONIC THERAPEUTIC, INC.	-2.39%	235M
VERTEX PHARMACEUTICALS INCORPORATED	+16.44%	122B
REGENERON PHARMACEUTICALS, INC.	+19.30%	115B
ARGENX SE	+21.22%	26.64B
BIONTECH SE	-23.70%	19.91B
GENMAB A/S	-17.47%	16.32B
WUXI APPTEC CO., LTD.	-45.95%	15.52B
BEIGENE, LTD.	-18.35%	15.49B
SAREPTA THERAPEUTICS, INC.	+64.16%	14.83B
NEUROCRINE BIOSCIENCES, INC.	+2.31%	13.67B

Bio Therapeutic Drugs